169 related articles for article (PubMed ID: 12576870)
1. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Nelson JB; Nabulsi AA; Vogelzang NJ; Breul J; Zonnenberg BA; Daliani DD; Schulman CC; Carducci MA
J Urol; 2003 Mar; 169(3):1143-9. PubMed ID: 12576870
[TBL] [Abstract][Full Text] [Related]
2. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
3. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
Carducci MA; Padley RJ; Breul J; Vogelzang NJ; Zonnenberg BA; Daliani DD; Schulman CC; Nabulsi AA; Humerickhouse RA; Weinberg MA; Schmitt JL; Nelson JB
J Clin Oncol; 2003 Feb; 21(4):679-89. PubMed ID: 12586806
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
5. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
[TBL] [Abstract][Full Text] [Related]
6. Atrasentan for metastatic hormone refractory prostate cancer.
Murphy G
Issues Emerg Health Technol; 2005 Dec; (77):1-4. PubMed ID: 16544441
[TBL] [Abstract][Full Text] [Related]
7. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period.
Nguyên-Pascal ML; Thomas JL; Bergougnoux L; Garnero P; Drapier-Faure E; Delmas PD
Climacteric; 2005 Jun; 8(2):136-45. PubMed ID: 16096169
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Michaelson MD; Kaufman DS; Kantoff P; Oh WK; Smith MR
Cancer; 2006 Aug; 107(3):530-5. PubMed ID: 16804927
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers.
Withold W
Eur J Clin Chem Clin Biochem; 1996 Oct; 34(10):785-99. PubMed ID: 8933101
[TBL] [Abstract][Full Text] [Related]
10. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
Berruti A; Dogliotti L; Bitossi R; Fasolis G; Gorzegno G; Bellina M; Torta M; Porpiglia F; Fontana D; Angeli A
J Urol; 2000 Oct; 164(4):1248-53. PubMed ID: 10992374
[TBL] [Abstract][Full Text] [Related]
11. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Carducci MA; Saad F; Abrahamsson PA; Dearnaley DP; Schulman CC; North SA; Sleep DJ; Isaacson JD; Nelson JB;
Cancer; 2007 Nov; 110(9):1959-66. PubMed ID: 17886253
[TBL] [Abstract][Full Text] [Related]
12. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Carducci MA; Jimeno A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
[TBL] [Abstract][Full Text] [Related]
13. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
Lara PN; Ely B; Quinn DI; Mack PC; Tangen C; Gertz E; Twardowski PW; Goldkorn A; Hussain M; Vogelzang NJ; Thompson IM; Van Loan MD
J Natl Cancer Inst; 2014 Apr; 106(4):dju013. PubMed ID: 24565955
[TBL] [Abstract][Full Text] [Related]
14. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P
Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417
[TBL] [Abstract][Full Text] [Related]
15. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
16. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
17. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
[TBL] [Abstract][Full Text] [Related]
19. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
Nelson JB; Love W; Chin JL; Saad F; Schulman CC; Sleep DJ; Qian J; Steinberg J; Carducci M;
Cancer; 2008 Nov; 113(9):2478-87. PubMed ID: 18785254
[TBL] [Abstract][Full Text] [Related]
20. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
